Top

Radiation Oncology

Published in:

Open Access 01-12-2012 | Research

Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer

Authors: Pedro J Prada, Lucia Mendez, José Fernández, Herminio González, Isabel Jiménez, Elisabeth Arrojo

Published in: Radiation Oncology | Issue 1/2012

Abstract

Background

Biochemical control from series in which radical prostatectomy is performed for patients with unfavorable prostate cancer and/or low dose external beam radiation therapy are given remains suboptimal.

The treatment regimen of HDR brachytherapy and external beam radiotherapy is a safe and very effective treatment for patients with high risk localized prostate cancer with excellent biochemical control and low toxicity.

Available only for authorised users

Morgan WR, Bergstralh EJ, Zincke H: Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 1993, 41: 113-120. 10.1016/0090-4295(93)90159-8CrossRefPubMed

Gerber GS, Thisted RA, Chodak GW, et al.: Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997, 32: 385-390.PubMed

Hanks GE, Diamond JJ, Kual JM, et al.: 17 ten-year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States. Int J Radiat Oncol Biol Phys 1987,13(4):499-505. 10.1016/0360-3016(87)90063-0CrossRefPubMed

Pollack A, Zagars GK: External beam radiotherapy dose-response of prostate cancer. Int J Radiat Oncol Biol Phys 1997,39(5):1011-1018. 10.1016/S0360-3016(97)00508-7CrossRefPubMed

Pollack A, Zagars GK, Smith LG, et al.: Preliminary results of a randomized radiotherapy dose escalation study comparing 70 Gy to 78 Gy for prostate cancer. J Clin Oncol 2000,18(23):3904-3911.PubMed

Hanks EG, Hanlon AL, Pinover WH, et al.: Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiot Oncol Biol Phys 2000,46(4):823-832. 10.1016/S0360-3016(99)00498-8CrossRef

Hanks GE, Martz KL, Diamond JJ: The effect of dose on local of prostate cancer. Int J Radiat Oncol Biol Phys 1988,15(6):1299-1305. 10.1016/0360-3016(88)90224-6CrossRefPubMed

Brenner DJ, Martinez AA, Edmundson GK, et al.: Direct evidence that prostate tumors show a high sensitivity to fractionation (low α/β), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002,52(1):6-13. 10.1016/S0360-3016(01)02664-5CrossRefPubMed

American Joint Committee on cancer: Prostate. In AJCC Cancer Staging Manual. 4th edition. Edited by: Beahrs OH, Henson DE, Htter RVP, Kennedy BJ. Philadelphia: Lippincott-Raven; 1992:181-186.

10.

Zelefsky MJ, Leibel SA, Gaudin PB, et al.: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998, 41: 491-500. 10.1016/S0360-3016(98)00091-1CrossRefPubMed

11.

Roach M, Hanks G, Thames H, et al.: Defining biochemical failure following radiotherapy with or without hormonal Therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65: 965-974. 10.1016/j.ijrobp.2006.04.029CrossRefPubMed

12.

Cox DR: Regression models and life-tables. J R Stat Soc B 1972, 34: 187-220.

13.

Kuban DA, Tucker SL, Dong L, et al.: Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70: 67-74. 10.1016/j.ijrobp.2007.06.054CrossRefPubMed

14.

Zelefsky MJ, Fuks Z, Hunt M, et al.: Margie Hunt et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urology 2001, 166: 876-881. 10.1016/S0022-5347(05)65855-7CrossRef

15.

Hanks GE, Hanlon AL, Pinover WH, et al.: Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 2000,46(4):823-832. 10.1016/S0360-3016(99)00498-8CrossRefPubMed

16.

Dearnaley DP, Hall E, Lawrence D, et al.: Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005, 92: 488-498.PubMedCentralCrossRefPubMed

17.

Sathya JR, Davis IR, Julian JA, et al.: Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005, 23: 1192-1199. 10.1200/JCO.2005.06.154CrossRefPubMed

18.

Zietman AL, DeSilvio ML, Slater JD, et al.: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294: 1233-1239. 10.1001/jama.294.10.1233CrossRefPubMed

19.

Martinez A, Gonzalez J, Spencer W, et al.: Conformal High dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urology 2003, 169: 974-980. 10.1097/01.ju.0000052720.62999.a9CrossRef

20.

Galalae RM, Kovács G, Schultze J, et al.: Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using High-dose- rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2002, 52: 81-90. 10.1016/S0360-3016(01)01758-8CrossRefPubMed

21.

Dattoli M, Wallner K, True L, et al.: Long-term outcome after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 2007,110(3):551-555. 10.1002/cncr.22810CrossRefPubMed

22.

Mate TP, Gottesman JE, Hatton J, et al.: High dose-rate after loading 192 iridium prostate brachytherapy: Feasibility report. Int J Radiat Oncol Biol Phys 1998, 41: 525-533. 10.1016/S0360-3016(98)00097-2CrossRefPubMed

23.

Stock RG, Cesareti JA, Hall SJ, Stone NN: Outcome for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int 2009, 104: 1631-1636. 10.1111/j.1464-410X.2009.08661.xCrossRefPubMed

24.

Roehl KA, Han M, Ramos CG, et al.: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: Long-term results. J Urol 2004, 172: 910-914. 10.1097/01.ju.0000134888.22332.bbCrossRefPubMed

25.

Han M, Partin AW, Zahurak M, et al.: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003, 169: 517-523. 10.1016/S0022-5347(05)63946-8CrossRefPubMed

26.

Partin AW, Pound CR, Clemens JQ, et al.: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins Experience after 10 years. Urol Clin N Am 1993, 20: 713-725.

27.

Kernen KM, Miles BJ: Prostate cancer treatment outcomes after radical prostatectomy: The Baylor experience (Abstr). Radiother Oncol 2000,55(Suppl 1):7-8.CrossRef

28.

Walz J, Joniau S, Chun FK, et al.: Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 2010, 107: 765-770.CrossRefPubMed

29.

Ficarra V, Novara G, Artibani W, et al.: Retropubic laparoscopy, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 2009, 55: 1037-1063. 10.1016/j.eururo.2009.01.036CrossRefPubMed

30.

Merrick GS, Butler WM, Galbreath RW, et al.: Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk features? BJU Int 2003,91(1):23-29. 10.1046/j.1464-410X.2003.04024.xCrossRefPubMed

31.

Martinez A, Galalae R, Gonzalez J, et al.: No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with high total radiation dose. J Urol 2003,170(6):2296-2301. 10.1097/01.ju.0000096709.05800.48CrossRefPubMed

32.

Bolla M, Collette L, Blank L, et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002, 360: 103-106. 10.1016/S0140-6736(02)09408-4CrossRefPubMed

33.

Denham JW, Steigler A, Lamb DS, et al.: Shortterm androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomized controlled trial. Lancet Oncol 2005,6(11):841-850. 10.1016/S1470-2045(05)70348-XCrossRefPubMed

34.

Pilepich MV, Winter K, Lawton CA, et al.: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long term results of Phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005,61(5):1285-1290. 10.1016/j.ijrobp.2004.08.047CrossRefPubMed

35.

Prada PJ, Fernández J, Martínez A, et al.: Transperineal injection of hyaluronic acid in the anterior peri-rectal fat to decease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 2007,69(1):95-102. 10.1016/j.ijrobp.2007.02.034CrossRefPubMed

Title: Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer
Authors: Pedro J Prada
Lucia Mendez
José Fernández
Herminio González
Isabel Jiménez
Elisabeth Arrojo
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2012
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-7-31

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer

Abstract

Background

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Please log in to get access to this content

Other articles of this Issue 1/2012

Computed tomography-guided permanent brachytherapy for locoregional recurrent gastric cancer

Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups

Wound healing after radiation therapy: Review of the literature

Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer

Scoring system predictive of survival for patients undergoing stereotactic body radiation therapy for liver tumors

Photon activated therapy (PAT) using monochromatic Synchrotron x-rays and iron oxide nanoparticles in a mouse tumor model: feasibility study of PAT for the treatment of superficial malignancy